Stay updated on HBV Drug SB 9200 Safety & Efficacy Clinical Trial

Sign up to get notified when there's something new on the HBV Drug SB 9200 Safety & Efficacy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the HBV Drug SB 9200 Safety & Efficacy Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a modification in the dosing cohorts for the Phase 2 study evaluating the safety, pharmacokinetics, and antiviral efficacy of SB 9200 in subjects infected with Chronic Hepatitis B Virus.
    Difference
    0.1%
    Check dated 2024-06-06T14:15:24.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as documented evidence of chronic HBV infection and exclusion criteria. Previously, this section had no information provided.
    Difference
    27%
    Check dated 2024-05-22T20:26:56.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:33:33.000Z thumbnail image

Stay in the know with updates to HBV Drug SB 9200 Safety & Efficacy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the HBV Drug SB 9200 Safety & Efficacy Clinical Trial page.